Please ensure Javascript is enabled for purposes of website accessibility

Gilead Sciences Disputes Claim That Remdesivir Failed in a COVID-19 Trial

By Prosper Junior Bakiny – Apr 24, 2020 at 5:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company noted that the trial in question had ended early, and asserted that the data was being misinterpreted.

Gilead Sciences (GILD -0.76%) issued a statement Friday disputing reports that its antiviral drug remdesivir was found to be ineffective as a treatment for COVID-19 in a clinical trial conducted in China.

News of the alleged clinical trial failure started making the rounds this week after a summary of data from the study was accidentally posted on the World Health Organization website. The data was eventually taken down, but not before many pundits jumped to conclusions as to the effectiveness (or lack thereof) of remdesivir. But in response, Gilead Sciences Chief Medical Officer Merdad Parsey said that "the post included inappropriate characterizations of the study." 

The study in question was supposed to involve patients with mild manifestations of COVID-19. However, the trial ended early due to low enrollment.  Parsey said that the data from this trial is currently being peer-reviewed, and Gilead Sciences should provide an update on it soon. Also, according to Parsey, the data from the trial was actually encouraging: "[T]rends in the data suggest a potential benefit for remdesivir, particularly among patients treated early."

Nurse holding test tube filled with blood for coronavirus testing.

Image Source: Getty Images.

Whatever investors make of all this, it is essential to note that remdesivir has shown some promise. STAT, a news website that focuses on the healthcare industry, recently reported that in a sample of 125 COVID-19 patients treated at University of Chicago Medicine with remdesivir (including 113 patients with severe cases of the disease), most of them recovered and were released from the hospital, while only two died.

However, that data was from only one section of a larger study, and has not yet been formally released. Until Gilead Sciences publishes full results from formal clinical trials, investors would be well-advised to take all such reports -- both positive and negative -- with a grain of salt. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences Stock Quote
Gilead Sciences
$64.95 (-0.76%) $0.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.